Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins

Title:Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins

Volume: 19 Issue: 13

Author(s): Qun Zhou*

Affiliation:

• Protein Engineering, Biologics Research, Sanofi, Framingham, MA, 01701,United States

Keywords: Glycan-binding proteins, lectins, antibodies, clinical development, inflammation, autoimmune diseases, hematological malignancies.

Abstract: Background: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.

Objective: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets.

Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.

Cite this article as:

Zhou Qun*, Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450119666180308144313